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ARTICLE
Targeted NUDT5 inhibitors block hormone
signaling in breast cancer cells
Brent D.G. Page1, Nicholas C.K. Valerie 1, Roni H.G. Wright2,3, Olov Wallner1, Rebecka Isaksson1,
Megan Carter4, Sean G. Rudd 1, Olga Loseva1, Ann-Sofie Jemth1, Ingrid Almlöf1, Jofre Font-Mateu2,3,
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Hanna Axelsson6, Shruti Regmi6, Anna-Lena Gustavsson6, Thomas Lundbäck6, Martin Scobie1, Kia Strömberg1,
Pål Stenmark4, Miguel Beato2,3 & Thomas Helleday1
With a diverse network of substrates, NUDIX hydrolases have emerged as a key family of
nucleotide-metabolizing enzymes. NUDT5 (also called NUDIX5) has been implicated in ADP-
ribose and 8-oxo-guanine metabolism and was recently identified as a rheostat of hormone-
dependent gene regulation and proliferation in breast cancer cells. Here, we further elucidate
the physiological relevance of known NUDT5 substrates and underscore the biological
requirement for NUDT5 in gene regulation and proliferation of breast cancer cells. We
confirm the involvement of NUDT5 in ADP-ribose metabolism and dissociate a relationship
to oxidized nucleotide sanitation. Furthermore, we identify potent NUDT5 inhibitors, which
are optimized to promote maximal NUDT5 cellular target engagement by CETSA. Lead
compound, TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and
subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells.
We herein present TH5427 as a promising, targeted inhibitor that can be used to further
study NUDT5 activity and ADP-ribose metabolism.
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T
he NUDIX hydrolases are a core family of nucleotide-
metabolizing enzymes that have critical roles in health and
disease1–3. With a diverse network of substrates, NUDIX
enzymes hydrolyze nucleoside diphosphates that are linked to a
variable group (X), and contain the NUDIX box motif:
GX5EX7REUXEEXGU, where X can be any residue and U
represents a hydrophobic residue (usually Leu, Val, or Ile)1,2. The
22 different NUDIX enzymes have been implicated in a variety of
biological processes1,2,4, including nucleotide pool sanitation and
the efficacy of antimetabolite chemotherapeutics5,6. The best-
53BP1
γH2A.X
RPA
siNeg siNUDT5 #1 siNUDT5 #7
2-O
HA
TP
2-O
Hd
AT
P
8-o
xo
dG
DP
8-o
xo
dG
TP
8-o
xo
GT
P
dA
TP
dG
TP GD
P
GT
P 
AD
PR
0
50
100v/
[E
to
t] (
mi
n–
1 )
150
200
250
300
350
400
MTH1
NUDT5
siN
eg
siN
UD
T5
 #1
siN
UD
T5
 #7
0
2
4
6
8
10
12
53
BP
1 
fo
ci/
bo
di
es
pe
r n
uc
le
us
NS
NS
siN
eg
siN
UD
T5
 #1
siN
UD
T5
 #7
2–5
2–6
2–7
2–8
2–9
2–10
2–11
2–12
2–4
2–5
2–6
2–7
2–8
2–9
2–10
2–11
2–12
2–4
In
te
ns
ity
 p
er
 n
uc
le
us
 (a
.u.
)
****
NS
***
siN
eg
siN
UD
T5
 #1
siN
UD
T5
 #7
****
RPAγH2A.X 53BP1
siN
UD
T5
#7
0
DM
SO
+s
iNe
g 500
 nM
TH
157
9
siN
UD
T5
#1
3
6
9
13
15
R
el
at
iv
e 
ta
il 
m
om
en
t
****
NS
NS
8
6
4
2
0
8 8-oxo-dGDP
ADPR
8-oxo-dGDP + NUDT5
ADPR + NUDT5
6
4
2
A260(mAU)
tR (min)
0
987
9 10 1186 7
8
6
4
2
0
9 10 1186 7
654
8
6
4
2
0
987
AMP
654
–/+ siRNA
72 hrs
Lysis Enzymatic reaction(+ ADPR) 
MeOH
precipitation
96-well plateHPLC analysis 
0 20 40 60 80 100 120
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
AD
Pr
 re
m
ai
ni
ng
Time elapsed (minutes)
Vehicle
siNon-targeting
siNUDT5 #1
siNUDT5 #7
siNUDT5 #1 + NUDT5
siNUDT5 #7 + NUDT5
37-
NUDT5
β-actin
NUDT5
β-actin
25-
37-
50-
kDa
DMSO/siNeg
TH1579
siNUDT5 #1
siNUDT5 #7
Buffer + OGG1
TH
15
79
DM
SO
+s
iNe
g
siN
UD
T5
 #1
siN
UD
T5
 #7
siN
eg
.
#1 #7
a
kDa
siRNA (10 nM)
37-
25-
50-
37-
c d
fe
b
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02293-7
2 NATURE COMMUNICATIONS | (2018) 9:250 |DOI: 10.1038/s41467-017-02293-7 |www.nature.com/naturecommunications
characterized NUDIX enzyme, MTH1 (NUDT1, NUDIX
hydrolase 1), is a sanitizer of the nucleoside triphosphate pool,
responsible for degrading oxidized purine nucleotides to safe-
guard nucleic acid integrity7–9. Important roles for other NUDIX
family members continue to be uncovered and highlight the
essential role of sanitation enzymes in nucleotide biochemistry10.
Similar to MTH1, NUDT5 (NUDIX hydrolase 5 or NUDIX5)
has been linked to key processes involved in nucleotide meta-
bolism and cancer11,12. Two predominant substrates have been
identified for NUDT5: 8-oxo-dGDP and adenosine 5′dipho-
sphoribose (ADPR)13–17. While there is evidence that NUDT5
can hydrolyze 8-oxo-dGDP under basic conditions (pH ≈ 10)13,
the physiological role of NUDT5 in 8-oxo-guanine metabolism
has not been rigorously studied13,18. ADPR is an important sig-
naling molecule in cells and is linked to the DNA damage
response through the activity of poly(ADPR) (PAR)-related
enzymes19–21. NUDT5 (and NUDT9) catalyze the breakdown of
ADPR to ribose-5-phosphate (R5P) and adenosine 5′-mono-
phosphate (AMP)17,22, which permits recovery of NAD+ pools
after DNA damage and poly(ADPR) polymerase (PARP) activa-
tion21. In addition, NUDT5 was recently shown to be responsible
for the production of PAR-mediated nuclear ATP and, thus,
subsequent ATP-dependent chromatin remodeling and gene
regulation following progestin or estrogen stimulation in breast
cancer cells23.
Here we investigate the roles of NUDT5 in 8-oxo-guanine and
ADPR metabolism. We demonstrate that NUDT5 poorly cata-
lyzes the hydrolysis of 8-oxo-dGDP under physiological pH
in vitro. Similarly, knockdown of NUDT5 fails to induce DNA
damage or influence OGG1-specific lesions in DNA, suggesting
that NUDT5 may be dispensable for maintaining genome
integrity via 8-oxo-guanine sanitation. Instead, we provide addi-
tional support that NUDT5 is an integral component of ADPR
metabolism. To further explore NUDT5 biology, we develop
targeted NUDT5 inhibitors via a cellular thermal shift assay
(CETSA)-guided screening funnel and utilize these compounds to
study the role of NUDT5 in progestin-stimulated breast cancer
cells. Lead compound, TH5427, is a versatile NUDT5 probe that
can shed new light on nuclear ATP dynamics and ADPR-related
metabolism in cells.
Results
NUDT5 is a regulator of ADPR metabolism. While both 8-oxo-
dGDP and ADPR have been identified as potential
NUDT5 substrates, experiments under physiological conditions
have been largely absent from the scientific literature. To help
clarify the preferred substrate(s) for NUDT5, we screened perti-
nent canonical and oxidized nucleotide species, as well as ADPR,
at physiological pH (7.5) using an enzyme-coupled malachite
green-based assay (herein called simply the MG assay, Fig. 1a)
with purified human NUDT5 and MTH1 (Supplementary Fig. 1).
Distinct from MTH1, NUDT5 had negligible activity against all
tested oxidized and canonical nucleoside diphosphate and tri-
phosphate species but catalyzed efficient turnover of ADPR.
HPLC analysis confirmed the release of AMP as the expected
product of NUDT5-mediated ADPR hydrolysis (while R5P is not
detectable; Fig. 1b)24. Accordingly, no activity was observed with
8-oxo-dGDP by HPLC (Fig. 1b).
Furthermore, siRNA-mediated knockdown of NUDT5 alone
did not appreciably induce DNA damage signaling in U-2 OS
cells, as measured by multiple DNA damage markers (γH2A.X,
53BP1 and chromatin-bound RPA; Fig. 1c). In fact, γH2A.X and
RPA signals generally decreased to some extent. In addition,
genome integrity and OGG1-specific DNA lesions were unaf-
fected by NUDT5 depletion in the modified alkaline comet assay
(Fig. 1d), which was in stark contrast to treatment with the
MTH1 inhibitor, TH1579 (karonudib)25. Altogether, these data
suggest that (1) 8-oxo-dGDP is a poor substrate for NUDT5 at
physiological pH and (2) that NUDT5 is not critical for oxidized
nucleoside pool sanitation under these conditions.
We then used HPLC to monitor ADPR hydrolysis in U-2 OS
cell lysates, which emulated the cellular context and was based on
an earlier procedure performed in yeast26 (schematic illustration
in Fig. 1e). Following depletion with NUDT5 siRNAs prior to cell
lysis, ADPR hydrolysis was markedly attenuated compared to
non-targeting siRNA controls. As expected, this could be rescued
by the addition of recombinant NUDT5 protein (Fig. 1f),
indicating that NUDT5 plays an important role in cellular ADPR
turnover.
Small molecule screening campaign for NUDT5 inhibitors. We
next sought to develop small molecule NUDT5 inhibitors to
further probe the role of NUDT5 in ADPR metabolism. A high-
throughput, screening-compatible NUDT5 inhibition assay was
established using slight modifications to the aforementioned MG
procedure (Fig. 2a)15,27. Briefly, ADPR, NUDT5 and calf intest-
inal alkaline phosphatase (CIP) were combined in a coupled
enzymatic assay, as described in the online methods. In turn,
ADPR was hydrolyzed to AMP and R5P by NUDT5, and the
released R5P was further degraded to ribose and inorganic
phosphate (Pi) by CIP. Free Pi was subsequently detected using
the malachite green reagent. The screen was conducted using a
combination of the Chemical Biology Consortium of Sweden
(CBCS) primary screening set and several commercial libraries
from Enamine, TimTec, Maybridge and ChemDiv. In total, ~72
000 distinct chemical entities were screened for their potential
Fig. 1 NUDT5 is a key regulator of ADP-ribose metabolism. a Hydrolysis of potential oxidized nucleotides and nucleotide-sugar substrates by MTH1 (blue)
and NUDT5 (red), as measured by the enzyme-coupled malachite green assay (MG assay), at pH 7.5. A representative experiment (of n= 2) with mean±
SD and individual values of quadruplicate replicates is shown. b Representative HPLC traces of NUDT5-mediated ADPR (red) and 8-oxo-dGDP (blue)
hydrolysis to AMP or 8-oxo-dGMP, respectively (n= 2). c Top: Representative, pseudo-colored immunofluorescence stainings for γH2A.X, chromatin-
bound RPA, and 53BP1 in U-2 OS cells following treatment with negative control siRNA (siNeg) or NUDT5 siRNA (siNUDT5 #1, siNUDT5 #7) for 72 h.
Scale bar= 20 µm. Bottom: Quantification of γH2A.X, chromatin-bound RPA, and 53BP1 staining intensity in cells representing three independent
experiments (cells scored: γH2A.X, n= 871; RPA, n= 463; 53BP1, n= 981). Lines represent median fluorescence (and interquartile range for 53BP1); a.u.
arbitrary units. NS not significant, ***p< 0.001, ****p< 0.0001; Kruskal-Wallis test). d Top: Representative, pseudo-colored images of treated U-2 OS cells
following the modified alkaline comet assay and confirmation of NUDT5 knockdown with a cropped western blot. Scale bar= 50 µm. Bottom:
Quantification of the tail moment (relative to the DMSO+siNeg, buffer-treated control) from two independent experiments performed in duplicate
(minimum of 100 cells per slide per condition). Buffer-treated samples are shown in blue, OGG1-treated samples in red. Lines represent median tail
moments. ****p< 0.0001 by Kruskal–Wallis test comparing OGG1-treated samples. e A graphical procedure depicting the analysis of ADPR hydrolysis in
cell lysates by HPLC. f ADP-ribose hydrolysis in U-2 OS cells alone (black, solid and dotted), following depletion with two different NUDT5 siRNAs (blue,
solid and dotted) or siRNA-treated cells complemented with purified NUDT5 protein (red, solid and dotted), as quantified by HPLC. A representative
chromatogram is shown (of n= 2 independent experiments) and NUDT5 knockdown confirmation with cropped western blot
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inhibition of NUDT5 at a concentration of 10 µM (Supplemen-
tary Table 1, Supplementary Fig. 2a, b). Execution of this
screening campaign was split between two different occasions.
The screening performance in the two screening campaigns was
excellent (average z´ factors of 0.87 and 0.85, Supplementary
Fig. 2c), resulting in a hit limit as defined by the average and three
standard deviations of the library compound responses of 10.1
and 18.4% inhibition, respectively (Supplementary Table 1,
Supplementary Fig. 2a, b). This translated to 53 and 475 hits (0.3
and 0.8% hit rate, respectively), yielding 528 total hits from the
2 separate screening occasions.
Preliminary optimization of hit compounds. Of the 528 hit
compounds, 71 compounds possessed a theophylline group,
which was identified as a key functional group for NUDT5
inhibition. The most potent compound, 1 (TH1167, MG assay
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Fig. 2 Development of potent NUDT5 inhibitors from a high-throughput screening campaign. a A representation of the enzyme-coupled malachite green
assay (MG assay). ADPR is hydrolyzed to AMP and R5P by NUDT5, then R5P is converted to free inorganic phosphate detected by the malachite green
reagent. b Preliminary structure–activity relationship study for determining where modifications are tolerated. Favorable optimization of TH1167 was
performed by modification at the theophylline 8-position (purple) and tail position (green) of the molecule. MG assay IC50 values are reported below the
chemical structures. c Structure of NUDT5 with inhibitor TH1713. Binding of TH1713 (orange) by NUDT5 dimer (chain A, limon green and chain B, green)
through stacking between Trp28 of chain A and Trp46 of chain B and hydrogen bonds to the amide nitrogen of Glu47 and side chain of Arg51. An alternate
conformation of the methylbenzene modality is modeled in gray. d NUDT5 inhibitor screening funnel optimized to select for target engagement in cells
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IC50 = 0.58 µM, depicted in Fig. 2b), was selected for optimization
in structure–activity relationship (SAR) studies. Preliminary
medicinal chemistry efforts aimed to increase the potency of
TH1167. Four major sites were identified for diversification: (1)
the theophylline portion (blue), (2) the 8-position of the theo-
phylline ring (purple), (3) the linker region (orange), and (4) the
tail position of the molecule (green), depicted in Fig. 2b. The
theophylline moiety of TH1167 was deemed necessary for com-
pound activity due to the high number of hit compounds that
possessed this functional group. Incorporation of additional
functionality at the 8-position of the theophylline ring was well-
tolerated and led to improved inhibitory activity. The 8-
dimethylamino variant, 2 (TH1713, MG assay IC50 = 70 nM,
Fig. 2b), had more than 8-fold greater potency over TH1167.
While replacing the oxadiazole ring with other linker groups did
not improve NUDT5 inhibition, derivatization of the tail or 5-
position of the oxadiazole ring led to increased potency (Fig. 2b).
The most active tail derivative, 3 (TH1533) incorporated the 3,4-
dichlorobenzene group as the optimal tail and was equipotent
with TH1713.
To put these inhibitors into perspective, we also tested
compounds that were previously reported to inhibit NUDT5
and/or NUDT9 activity in HeLa cell extracts21, which included
chelerythrine (a PKC inhibitor), LY294002 (a PI3K inhibitor), p-
coumaric acid and flavone. None of these had any direct
inhibitory effect on NUDT5 activity in the enzyme-coupled
malachite green assay (IC50 values>100 µM; Supplementary
Fig. 3).
Cellular target engagement. Next, we sought to further char-
acterize NUDT5 inhibitors with biophysical techniques to deter-
mine if they would bind the intended target in a cellular setting.
Target engagement assays, such as the cellular thermal shift assay
(CETSA), have allowed for unprecedented understanding of
ligand-target interactions in live cells28. We first verified that the
inhibitors could stabilize NUDT5 against thermal denaturation
using differential scanning fluorimetry (DSF). Preliminary lead
compounds TH1533 and TH1713 each resulted in a 5 °C shift in
melting temperature (Tm) at 20 µM compound concentrations
(Supplementary Fig. 4a), indicating inhibitor binding.
To establish a protocol for cellular target engagement, intact
HL-60 cells and cell lysates were subjected to a temperature
gradient and soluble NUDT5 levels were assessed by western blot
with thermostable SOD1 as a loading control (Supplementary
Fig. 4b). For the purpose of screening, 83 °C was selected as the
ideal temperature to evaluate NUDT5 engagement, as nearly all of
the protein had aggregated at this temperature. The high
temperatures that were required to induce NUDT5
unfolding were also found to compromise cell membrane
integrity (Supplementary Fig. 4c), thus cells were washed twice
with PBS in order to remove excess compound before the
transient heating step. Without such additional precautions, the
binding studies would be severely compromised by the leaking
membranes29.
TH1167 was a potent inhibitor in vitro but did not show
sufficient target engagement in cell lysates or intact cells at 83 °C
(Supplementary Fig. 4d). Synthetic derivatives, TH1713 and
TH1533, had more potent biochemical activity and could stabilize
NUDT5 against thermal degradation in vitro; however, only
TH1533 showed activity by CETSA in intact cells (Supplementary
Fig. 4d). Encouraged by the result with TH1533, we sought to
further optimize these compounds to increase NUDT5 target
engagement under the described conditions. TH1533 and
TH1713 both suffered from very poor solubility, which also
necessitated further medicinal chemistry efforts.
Structural insight to inhibitor design. To confirm the binding
modality of the NUDT5 inhibitors and help guide further inhi-
bitor development, NUDT5 was crystallized in complex with
TH1713, and the structure was solved at 2.2 Å resolution (Fig. 2c,
Supplementary Fig. 5 and Table 1). TH1713 occupies the same
binding regions as ADPR within the active site of the NUDT5
dimer30, which is comprised of residues from chain A and chain
B. The theophylline ring of TH1713 is anchored in place by two
hydrogen bonds between its carbonyl oxygen atoms and the
amide nitrogen of Glu47 (chain B), as well as the guanidinyl
group of Arg51 (chain A). Pi stacking interactions between the
theophylline ring and the indole rings of Trp28 (chain A) and
Trp46 (chain B) further strengthen inhibitor binding. The oxa-
diazole group demonstrates variable water coordination and the
3-methylbenzene group extends into a hydrophobic cavity where
it rotates between two alternate orientations. The 8-
dimethylamino group on the theophylline ring extends out of
the active site towards the solvent, which provides insight into the
observed tolerability of modifications at this position.
Utilizing progressive CETSA to drive compound optimization.
A screening funnel was designed to prioritize compounds that
engaged NUDT5 under progressively more stringent biological
conditions (Fig. 2d). After first assessing biochemical inhibition of
NUDT5 using the MG assay, compounds with an IC50<100 nM
were tested for their ability to thermostabilize NUDT5 in cell
lysates at single doses by high-throughput CETSA (HT-CETSA).
This approach allowed for practical screening of inhibitors and
quickly identified compounds that could bind to NUDT5 in a
biologically demanding setting. Compounds that showed
engagement in cell lysates were then evaluated at a single con-
centration to determine if they could engage NUDT5 in intact
cells. Finally, isothermal dose-response fingerprint CETSA
(ITDRFCETSA) was performed to establish which inhibitors could
Table 1 Crystallography data collection and refinement
statistics (molecular replacement)
NUDT5 TH1713 NUDT5 TH5427
Data collection
Space group C 1 2 1 C 1 2 1
Cell dimensions
a, b, c (Å) 111.5, 39.3, 98.72 100.6, 40.1, 104.1
α, β, γ (°) 90, 122.2, 90 90, 113.4, 90
Resolution (Å) 41.8–2.2 (2.3–2.2)a 46.2–2.6 (2.8–2.6)a
Rsym or Rmerge 10.9 (96.5) 7.5 (59.9)
I /σI 9.7 (1.4) 15.6 (2.5)
Completeness (%) 96.6 (93.2) 98.0 (95.6)
Redundancy 3.2 (2.8) 3.5 (3.6)
Refinement
Resolution (Å) 41.8–2.2 46.2–2.6
No. reflections 18626 11883
Rwork/Rfree 18.0/23.8 19.6/25.5
No. atoms
Protein 3037 3049
Ligand/ion 87 66
Water 174 46
B-factors
Protein 46.3 57.4
Ligand/ion 49.4 81.2
Water 87.5 42.7
R.m.s. deviations
Bond lengths (Å) 0.01 0.007
Bond angles (°) 1.5 1.3
aData for each structure was collected from single crystals. Highest-resolution shell is shown in
parentheses
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stabilize intracellular NUDT5 at the lowest concentrations.
Relying on cellular target engagement assays to select our top
compounds ensured that our medicinal chemistry campaign was
not biased towards compounds that caused a predefined pheno-
typic response.
A focused library of NUDT5 inhibitors incorporating char-
acteristics of both TH1533 and TH1713 was developed with the
aim of improving inhibitor activity and solubility. Novel NUDT5
inhibitors are displayed in Table 2 with their corresponding MG
assay IC50 values plotted in Fig. 3a (synthetic protocols can be
found in the Supplementary Methods). While the combination of
the 3,4-dichlorophenyl tail from TH1533 and the dimethylamino
group of TH1713 was moderately active in the MG assay (11, MG
assay IC50 = 0.11 µM), this compound also suffered from very
poor solubility, which likely contributed to its compromised
efficacy. Compound 13 also had major solubility issues and, as a
result, both compounds were excluded from further analysis.
The 16 NUDT5 inhibitors that met the IC50< 100 nM criterion
were subsequently screened for NUDT5 engagement at 20 µM in
HL-60 cell lysates. Relative NUDT5 levels in the presence of
compounds compared to a 37 °C control are shown in Fig. 3b. Of
the evaluated inhibitors, compounds 25 (TH5423, MG assay IC50
= 54 nM), 26 (TH5424, MG assay IC50 = 39 nM) and 28 (TH5427,
MG assay IC50 = 29 nM) showed the most stabilization of
NUDT5 in cell lysates. These compounds, as well as 4
(TH1659, MG assay IC50 = 20 nM but was unable to stabilize
NUDT5 above the 50 % cutoff) were then analyzed for target
engagement with intact cells. At 20 µM, TH5423, TH5424 and
TH5427 all stabilized NUDT5 to nearly the same levels as
observed in the 37 °C DMSO control (Fig. 3c), whereas
TH1659 showed a smaller degree of stabilization. ITDRFCETSA
illustrated that TH5427 was the most potent stabilizer under the
described conditions with an apparent EC50 of 2.1 µM (Fig. 3d).
Accordingly, TH5427 had a positive, dose-dependent shift in the
apparent Tagg—the temperature at which 50 % of the target
protein denatures and aggregates (TH5427 shifted NUDT5 Tagg
up to ≈ 8 °C; Supplementary Fig. 6). TH5423 and TH5424 could
also dose-dependently stabilize NUDT5, however much higher
concentrations were required. TH1659 demonstrated poor-to-
moderate stabilization of NUDT5 in lysates and intact cells and
was also distinctly toxic under tested conditions, which cast
further doubt on its potential as an adequately selective NUDT5-
targeted probe (Supplementary Fig. 7).
NUDT5 target engagement by DARTS. While thermal stabili-
zation assays are valuable methods for assessing target engage-
ment,the dependency on heating can alter protein folding and
ligand binding thermodynamics 31, i.e., the observed stabilization
may not be physiologically relevant. Because NUDT5 had very
high thermal stability (Supplementary Fig. 4b, Tagg ≈ 76–80 °C;
consistent with MS-CETSA proteomic profiling32), it was espe-
cially pertinent to verify that TH5427 could engage NUDT5 at
physiological temperatures. Drug affinity responsive target sta-
bility (DARTS)33 is an orthogonal assay based on the principle of
protein stabilization against protease degradation in a cell extract
Table 2 Small molecule inhibitors of NUDT5 combining aspects of TH1713 and TH1533
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(graphical procedure in Supplementary Fig. 8a). When added to
HL-60 cells in culture, TH5427 (at 0.74 and 2.2 µM) stabilized
NUDT5 against exogenous protease degradation following cell
lysis, indicating potent target engagement (Supplementary
Fig. 8b). In conjunction with the CETSA experiments, the
DARTS data demonstrates TH5427 engages NUDT5 at physio-
logical temperatures, further supporting its use as a targeted
NUDT5 inhibitor.
Crystal structure with lead NUDT5 inhibitor TH5427. A crystal
structure was obtained with TH5427 in the active site of NUDT5
(Fig. 3e, Supplementary Fig. 5b and Table 1). TH5427 bound in a
similar fashion to TH1713, with the same primary coordinating
interactions. The theophylline moiety is anchored in place by
stacking interactions between Trp28 (chain A) and Trp46 (chain
B) and two hydrogen bonds are observed between the theophy-
line carbonyl oxygen atoms and the amide nitrogen of Glu47
(chain B) and the guanidinyl group of Arg51 (chain A). As
expected, the piperazine moiety extended out from the active site
while the dichlorobenzene tail extended deep into a hydrophobic
pocket in a static position. Overall, the orientations of TH1713
and TH5427 were very similar and the additional functionality at
the tail and 8-positions did not cause drastic changes in the
binding modality (Supplementary Fig. 5b).
TH5427 selectivity. TH5427 was then screened in vitro against a
panel of NUDIX enzymes and other nucleotide phosphohy-
drolases for potential off-target activity. Outside of NUDT5,
TH5427 had the strongest activity against MTH1 (82 % inhibi-
tion) and gave 39, 66, and 38 % inhibition against dCTPase,
NUDT12 and NUDT14, respectively, at 100 µM (Supplementary
Fig. 1, Supplementary Fig. 9a). Of particular interest, TH5427 had
no effect on NUDT9-mediated hydrolysis of ADPR, indicating
discrimination amongst ADP-ribose hydrolases. Ensuing dose-
response analysis for MTH1 gave an IC50 of 20 µM (cf. 29 nM for
NUDT5), which results in an apparent 690-fold selectivity for
NUDT5 over MTH1 in vitro (Supplementary Fig. 9b). Accord-
ingly, 20 µM TH5427 treatment resulted in no thermal shift of
MTH1 by CETSA (Supplementary Fig. 9c).
TH5427 selectivity was further scrutinized with the Safe-
tyScreen 44 and ExpresSDiversity kinase panels from Eurofins
Cerep Panlabs, which cover common off-target interactions
typically seen during drug development and the diversity of the
human kinome, respectively. Screened at 10 µM, TH5427 only
displayed a few significant interactions within the chosen panels
(including neurotransmitter transporters and hERG; Supplemen-
tary Fig. 9d and e). Altogether, these data suggest that TH5427 is
a selective NUDT5 inhibitor with a promising safety profile.
Exploring NUDT5 in breast cancer with targeted inhibitors.
NUDT5 was recently identified as a key factor for the production
of ATP in the nucleus of breast cancer cells, and its depletion
blocked the regulation of progestin- and estrogen-dependent
genes23. Notably, production of ATP from 32P-PAR was
demonstrated using purified human NUDT5 and bovine PARG
in vitro, which formed the basis of NUDT5′s involvement in
hormone-dependent gene expression. Therefore, we first assessed
the inhibitory effect of TH5427 in this same setting. When ana-
lyzed by thin layer chromatography (TLC), TH5427 inhibited the
biochemical synthesis of ATP and AMP from 32P-PAR in the
presence of purified NUDT5, PARG and PPi (Fig. 4a, comparing
lanes 4 and 5; Supplementary Fig. 1). This underscores a funda-
mental biochemical importance for NUDT5 activity in PAR-
derived ATP synthesis.
To further demonstrate the utility of NUDT5-targeted probes,
we analyzed our top compounds within the context of hormone
signaling and breast cancer with T47D breast adenocarcinoma
cells. For these experiments, lead NUDT5 inhibitor, TH5427, was
used at 1.5 µM, whereas the less potent derivatives by CETSA,
TH5423 and TH5424, were used at 10-fold higher concentrations
(Fig. 4b). Similar to the target engagement experiments in HL-60
cells, TH5427 demonstrated the best ability to stabilize NUDT5 in
T47D cells (Supplementary Fig. 10a). Likewise, TH5423, TH5424
and TH5427 were generally non-toxic when used below 20 µM
(Supplementary Fig. 10b).
As NUDT5 activity is critical to elicit nuclear ATP production
following hormone stimulation23, we used a nuclear-targeted
luciferase reporter system to track nuclear ATP production after
hormone treatment (Fig. 4c). Hormone-starved T47DWT cells
were incubated with NUDT5 inhibitors and then stimulated with
the progesterone receptor agonist, R5020, for the time points
indicated. While strong luminescence was observed in the cells
treated with TH5423, TH5424 and the DMSO control, cells
treated with TH5427 had a marked reduction in nuclear
luminescence, indicating impaired nuclear ATP production
(quantification Fig. 4c). This observation was consistent with
previously reported siRNA experiments that showed NUDT5
depletion also attenuated nuclear ATP synthesis23. Additionally,
the relative activity of the lead NUDT5 inhibitors was consistent
with target engagement assays, where 1.5 µM of TH5427 had
stronger effects than TH5423 or TH5424 at 15 µM.
Nuclear ATP feeds ATP-dependent chromatin remodeling
enzymes, which disrupt the interactions of histones and DNA23.
This process, in conjunction with histone acetyltransferase and
deacetylase complexes, regulates the transcriptional activation of
genes34–36. Blocking the production of nuclear ATP prevents the
activation of ATP-dependent chromatin remodeling enzymes and
displacement of histones H1 and H2A/H2B23. We therefore
analyzed histone displacement following hormone exposure in
T47DWT cells treated with NUDT5 inhibitors (Fig. 4d). While
moderate effects were seen with TH5423 and TH5424 (15 µM),
treatment with TH5427 at 1.5 µM inhibited histone H1
displacement.
Without chromatin remodeling, the regulation of hormone-
dependent genes and associated cell proliferation should also be
impaired23. Using T47D cells harboring an integrated mouse
mammary tumor virus luciferase reporter (MMTV-luc; T47DM
cells), mRNA expression for progestin-dependent genes (EGFR
and MMTV-luc) was compared to progestin-independent genes
(CCNB1 and RBM24) following 6 h of R5020 treatment (Fig. 4e).
Again, TH5427 significantly disrupted EGFR and MMTV-luc
expression following progestin stimulation but did not affect the
expression of CCNB1 or RBM24. TH5424 showed similar activity
to TH5427; however, TH5423 did not significantly disrupt
progestin-dependent gene regulation.
Finally, as a consequence of blocking transcriptional responses,
TH5427 treatment abrogated the progestin-dependent prolifera-
tion response in T47DWT cells, as measured by BrdU incorpora-
tion (Fig. 4f). Collectively, these experiments confirm NUDT5 as
an integral factor in progestin signaling and that TH5427 is a
potent NUDT5 inhibitor that blocks hormone-dependent gene
expression in breast cancer cells.
Discussion
Investigating the role of NUDT5 in breast cancer has highlighted
its importance in ADPR metabolism and hormone-dependent
gene regulation. While early reports provided biochemical evi-
dence that NUDT5 could hydrolyze 8-oxo-dGDP to 8-oxo-
dGMP14, we were unable to demonstrate similar activity under
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physiologically relevant conditions. This was in line with reported
suspicions that NUDT5 may have a limited cellular role in 8-oxo-
guanine metabolism13,37. Furthermore, we have determined that
NUDT5 depletion does not influence oxidized nucleotide content
of DNA or increase DNA damage signaling under our treatment
conditions, similar to previous studies with NUDT15 (MTH2)38.
While this evidence suggests NUDT5 is not essential for 8-oxo-
guanine sanitation, we cannot rule out situational contexts in
which it may be important; as NUDT5 is clearly capable of
hydrolyzing 8-oxo-dGDP in vitro13,14,16,24,30,37. On the other
hand, we provide additional support that NUDT5 knockdown
leads to impaired ADPR hydrolysis in cell lysates, which fits with
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previous reports pertaining to its role in ADPR
metabolism15,17,23.
To further study NUDT5, we developed potent, small molecule
inhibitors and probed their activity in cells with an emphasis on
avoiding phenotypic biases by relying on thermal shift assays to
evaluate inhibitor binding. Lead agent, TH5427, represents a
potent NUDT5 inhibitor that was developed using a combination
of target engagement techniques. This compound is non-toxic in
cell lines tested up to 20 µM (Supplementary Figs. 7 and 10b) and
does not have strong phenotypic effects when used in isolation.
Similar to RNAi depletion, TH5427 neither induced significant
DNA damage signaling nor increased OGG1-specific DNA
lesions in cells when compared to the MTH1 inhibitor, TH1579
(Supplementary Fig. 11a–c). However, in combination with
progestin stimulation, TH5427 blocked nuclear ATP synthesis,
impaired hormone-induced chromatin remodeling, and disrupted
progestin-dependent gene regulation and proliferation in T47D
breast cancer cells. Its effective concentration was 10-fold lower
than other synthesized NUDT5 inhibitors, consistent with our
ranking based on target engagement assays.
In the development of effective probes or drug molecules, an
important determinant of the quality and effectiveness relates to
their ability to engage specific targets within the cell39,40. Recently
developed and innovative target engagement assays (including
CETSA and DARTS), have the potential to drive medicinal
chemistry and drug discovery efforts, while also overcoming high
attrition rates and lack of clinical efficacy with first-in-class drugs
for validated targets41,42. This is reflected in recent paradigm
shifts within the pharmaceutical industry, which have prioritized
target engagement techniques to show drug efficacy in both pre-
clinical and clinical settings41. In addition, the value of CETSA as
a primary high-throughput screening assay was recently
demonstrated for thymidylate synthase inhibitors43, further
cementing cellular target engagement assays as powerful tools to
identify lead molecules.
Utilizing these state-of-the-art techniques led us to discover
TH5427, a potent and cell-active NUDT5 inhibitor that can be
used to further understand the role of NUDT5 in biological
systems. We have provided a proof of concept showing that
TH5427 blocks NUDT5-dependent processes in breast cancer
cells, and targeting NUDT5 may represent a promising new
therapeutic approach for breast cancer treatment. Ongoing efforts
are aimed at formulating NUDT5 inhibitors for in vivo use and
will focus on further investigating the role of NUDT5 in cancer
and other disease models.
Methods
Protein purification. Human NUDT5, NUDT12, NUDT14, NUDT15, and ITPase
bacterial expression constructs in pNIC28 were a kind gift from SGC Stockholm.
Human MTH1 (NUDT1) cDNA was codon optimized for Escherichia coli
expression (Life Technologies) and subcloned into pET28a(+). Human NUDT9
cDNA was produced from HL-60 cells and subcloned into the pET28a(+) bacterial
expression construct. All proteins contained N-terminal His-tags, were expressed
in E. coli BL21 (DE3) R3 pRARE2 at 18 °C and purified by the Protein Science
Facility (PSF) at the Karolinska Institute, Stockholm. Purification was performed
using HisTrap HP (GE Healthcare) followed by gel filtration with a HiLoad 16/60
Superdex 75 (GE Healthcare)4,9. Human dCTPase and dUTPase were expressed as
above but were purified using a HisTrap HP (GE Healthcare), the His-tag was
removed by thrombin (dUTPase) or TEV digestion (dCTPase) and both were
further purified by MonoQ ion exchange column9. Purity of the protein pre-
paration was examined using SDS-PAGE followed by Commassie staining and the
mass of the purified protein was determined using mass spectrometry. All purified
hydrolases were concentrated, aliquoted and stored in storage buffer (20 mM
HEPES, 300 mM NaCl, 10% glycerol, 1 mM TCEP, pH 7.5) at -80°C.
Purified GST-tagged human PARP1 and bovine PARG were produced with the
pBC-PARP-144 and pGEX-2T bPARG45 bacterial expression constructs,
respectively23. Bacteria were cultured in 100 mL LB overnight at 37 °C and 180
RPM. Once the OD600 reading approached 1 the following day, expression was
induced by the addition of IPTG (1 mM final concentration) and the cultures were
grown for an additional 3 h. GST fusion proteins were then purified by affinity
chromotography using a glutathione-Sepharose 4B resin and stored at -80 °C until
use.
In vitro analysis of substrate hydrolysis. Activity of NUDT5 and MTH1 with a
panel of potential substrates [2-OH-ATP, 2-OH-dATP, 8-oxo-dGDP, GDP and 8-
oxo-GTP (Jena Biosciences), 8-oxo-dGTP (TriLink Biotechnologies), dATP
(ThermoFisher Scientific), dGTP, GTP and ADPR (Sigma-Aldrich)] was assessed
in reaction buffer (100 mM Tris Acetate pH 7.5, 40 mM NaCl, 10 mM Mg Acetate)
at 22 °C. For ADPR, alkaline phosphatase from bovine intestinal mucosa (10 U/ml;
Sigma-Aldrich) was added as coupled enzyme, while other substrates were coupled
to E. coli pyrophosphatase (0.2 U/mL, Sigma-Aldrich). After 30 min incubation
with shaking, formed inorganic phosphate was detected by addition of malachite
green reagent27. Absorbance at 630 nm was read after 15 min incubation with
shaking using a Hidex Sense plate reader. The potency of NUDT5 inhibitors was
assessed similarly as above (and in the screening campaign) by monitoring ADPR
hydrolysis; details are in the Supplementary Information.
HPLC experiments were carried out with slight variations to previously
described methods5,46. 50 µM ADPR or 8-oxo-dGDP were incubated with or
without 6 nM NUDT5 in buffer containing 100 mM Tris-HCl, pH 7.4, 40 mM
NaCl, 10 mM MgCl2, 1 mM dithiothreitol and 0.005 % Tween 20. Samples were
incubated in 1.5 mL tubes in a water bath that was maintained at 37 °C and stirred
using magnetic stir bars. After 30 min, 40 µL of the reaction mixture was added to
60 µL of cold MeOH (−20 °C) to quench enzymatic activity. The quenched samples
were then cooled to −72 °C using an ethanol dry ice bath for several minutes.
Samples were then clarified using a small bench-top centrifuge, and the
supernatant (90 µL) was added to a fresh 1.5 mL tube. The water/methanol mixture
was evaporated by vacuum centrifugation at 60 °C. Samples were then resuspended
in ddH2O (90 µL), and transferred to a 96-well plate, which was then sealed
and placed in the auto-sampler for HPLC analysis (samples were kept at 4 °C prior
to injection).
The HPLC system was an Agilent 1100 equipped with an auto-sampler and a 5
µm C18 column, 4 × 125 mm column. Mobile phases consisted of a linear gradient
of solvents from 40% A: 60 % B, to 100% B over 10 min then at 100% B for 2 min
and a 3-minute equilibration back to 60 % B. Solvent A consisted of 10 mM
KH2PO4, 10 mM tetrabutylammonium hydroxide, at pH 6.9 in H2O, and Solvent B
consisted of 50 mM KH2PO4, 5.6 mM tetrabutylammonium hydroxide at pH 7.0 in
H2O and 30 % methanol. Absorbance detection at 260 nm was used to observe the
nucleotide species, retention times were verified using appropriate standards.
Cell lines and culturing conditions. U-2 OS osteosarcoma and HL-60 acute
promyelocytic leukemia cells were obtained from the American Type Culture
Collection (ATCC, Manassass, VA, USA), and T47D breast adenocarcinoma cells
(ER+/PR+/HER2-) were obtained from Karin Dahlman-Wright (Karolinska
Institutet). U-2 OS cells were cultured in DMEM high glucose, GlutaMAX medium
(Life Technologies/ThermoFisher Scientific), while HL-60 and T47D were cultured
in RPMI, GlutaMAX medium (Life Technologies/ThermoFisher Scientific). All
media were supplemented with 10% heat-inactivated fetal bovine serum (FBS) and
penicillin/streptomycin. Unless otherwise indicated, cell cultures were maintained
at 37 °C with 5% CO2 in a humidified incubator. The cells were routinely screened
for mycoplasma using the MycoAlert kit (Lonza Bioscience) and none were listed
on ICLAC or known to be cross-contaminated.
For hormone and inhibitor treatments, normal T47DWT cells or cells
containing a single copy of luciferase under the control of the mouse mammary
tumor virus (MMTV) promoter (T47DM) were used23. Prior to hormone
induction, cells were grown in phenol red-free RPMI medium supplemented with
10% dextran-coated charcoal-treated FBS (DCC/FBS). After 16 h in serum-free
conditions, cells were pre-incubated with DMSO (vehicle) or NUDT5 inhibitor for
2 h at the indicated dose before addition of R5020 (10 nM) or vehicle (ethanol,
EtOH) for the allotted time.
Antibodies and reagents. Purified NUDT5 was submitted for polyclonal antibody
production at EZBiolabs (USA). Anti-NUDT5 antibody was purified from rabbit
serum on a home-made affinity column with immobilized NUDT5 using an
AminoLink™ Immobilization Kit (cat. no. 44890, Thermo Scientific). Anti-beta
actin (β-actin, mouse monoclonal, cat. no. ab6276) and anti-53BP1 (rabbit poly-
clonal, cat. no. ab36823) were purchased from Abcam. Anti-γH2A.X (phospho-
Ser139, mouse monoclonal, JBW301, cat. no. 05-636) was purchased from Milli-
pore. Anti-SOD1 (rabbit polyclonal, FL-154, cat. no. sc-11407) was purchased from
Santa Cruz Biotechnology. Anti-53BP1 (rabbit polyclonal, cat. no. A300-272) was
purchased from Bethyl Laboratories. Anti-MTH1 (rabbit polyclonal, cat. no.
NB100-109) was purchased from Novus Biologicals. Anti-RPA32 (rat monoclonal,
cat. no. 2208S) and anti-Phospho-Histone H2A.X (Ser139; rabbit polyclonal, cat.
no. 2577) were purchased from Cell Signaling. Donkey anti-mouse IgG IRDye
680RD (cat. no. 925–68072) and goat anti-rabbit IgG IRDye 800CW (cat. no.
925–32211) were purchased from Li-Cor. Goat anti-rabbit IgG Alexa Fluor 488
(cat. no. A-11008) and donkey anti-mouse IgG Alexa Fluor 647 (cat. no. A-31571)
were purchased from ThermoFisher Scientific.
All NUDT5 inhibitors were dissolved in DMSO to a stock of 10 mM, and used
at the final concentrations and incubation times indicated. MTH1 inhibitor,
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Fig. 4 TH5427 inhibits progestin-dependent nuclear ATP synthesis in breast cancer cells. a Representative thin layer chromatography (TLC) of products
formed following processing of 32P-PAR by recombinant PARG and NUDT5 in the absence or presence of TH5427 and PPi in vitro (n= 2). b
Concentrations and structures of inhibitors used in T47DWT/M cell culture experiments. c Serum-starved T47DWT cells expressing Nuc-luc FRTTO
luciferase construct in the absence or presence of NUDT5 inhibitors prior to treatment with 10 nM R5020 and luminescence measurement. Top, a
representative, pseudo-colored image of bioluminescence intensity over 60min of R5020 treatment; bottom, box-and-whisker plots of bioluminescence
quantitations from six independent experiments (center line, median; box limits, upper and lower quartiles; whiskers, minima and maxima; individual data
points also shown). NS not significant, *p< 0.05, **p< 0.01, ***p< 0.001; repeated measures two-way ANOVA analysis. Control, gray, TH5423, blue,
TH5424, red, TH5427, orange. d Histone displacement was determined by chromatin immunoprecipitation (ChIP) using a histone H1-specific antibody
prior to (Starved, gray) or following 30min of R5020 (+R5020, blue) in the presence or absence of NUDT5 inhibitors in T47DM cells. Data from a
representative experiment is presented as mean fold change (+R5020/Starved)± SD of five different histone H1 contact regions. e Progesterone-
dependent and –independent gene expression analysis in the presence or absence (−) of NUDT5 inhibitors following R5020 treatment (6 h) by RT-qPCR
with T47DM cells. Data represents the mean± SEM log(mRNA abundance) normalized to serum-starved cells without R5020 treatment from three
(progesterone-dependent) or two (progesterone-independent) independent experiments. *p< 0.05, **p< 0.01; one-way ANOVA analysis. f R5020-
induced cell proliferation of T47DM cells in the absence or presence of NUDT5 inhibitors was assayed by BrdU incorporation after 24 h. Mean± SEM of
individual BrdU chemiluminescence signals are displayed without R5020 treatment (Starved, gray) and following R5020 treatment (+R5020, blue) from
two independent experiments. RLU; relative luminescence units. **p< 0.01, ****p< 0.0001; one-way ANOVA analysis
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TH1579 (karonudib)25, was dissolved in DMSO and used at a final concentration
of 500 nM and 24-hour incubation.
siRNA transfections. The siRNAs used in these studies were purchased from
Qiagen and are as follows:
AllStars Negative Control siRNA
siNUDT5 #1: 5′-CAAGAACCAACGGAATCTTCT-3′
siNUDT5 #7: Hs_NUDT5_7 Flexitube siRNA
siRNA transfection was performed using INTERFERin (Polyplus Transfection)
at a final concentration of 10 nM and for 72 h prior to read-out, following the
manufacturer’s instructions, unless otherwise noted.
ADPR hydrolysis in cell lysates by HPLC. Cell lysates were generated to study
NUDT5 enzymatic activities by HPLC based on earlier methods26. Briefly, 5 × 106
U-2 OS cells per experimental condition were harvested by trypsinization and
pelleted in microfuge tubes. siRNA was transfected for 72 h prior to analysis.
For analysis of cytosolic lysates, the cells were resuspended in 3–4 cell volume-
equivalents of lysis buffer (20 mM HEPES, pH 7.4, 50 mM NaCl, 10 mM MgCl2, 1
mM EDTA, 5% (v/v) glycerol, 0.3 M sucrose, 0.3 M ammonium sulfate
[(NH4)2SO4] and 1 mM dithiothreinol (DTT)) and incubated on ice for 15 min.
The cells were then lysed with 10-15 strokes of a dounce homogenizer and nuclei/
unlysed cells were pelleted by centrifugation for 10 min at 1000×g and 4 °C. The
supernatants were transferred to new microfuge tubes and further clarified for 25
min at 16,000×g and 4 °C. The cytosolic supernatants were then saved for
enzymatic analysis.
Lysates at cell concentrations of 5 × 107 cells/mL were diluted 1:4 in malachite
green assay buffer, pH 7.5, and 50 µM of substrate was added immediately before
analysis. The enzymatic reactions were then conducted the same as with the
in vitro studies for the indicated times. Enzymatic activity was then determined by
HPLC analysis.
Modified alkaline comet assay. The modified comet assay was used to determine
relative amounts of OGG1-specific substrates (e.g., 8-oxo-dG) within cellular
DNA9. U-2 OS cells were transfected with siRNA for 72 h and/or treated with
DMSO/500 nM TH1579 for 24 h prior to harvesting by trypsinization. For
experiments with TH5427, cells were treated for 24 or 72 h with 10 µM compound.
In brief, 120 µL of 1% agarose in PBS was added to one end of a fully-frosted
microscope slide (ThermoFisher Scientific) and protected with a 24 × 40 mm
coverslip to form the first layer. Once solidified at 4 °C, the second layer was made
by mixing 400 µL of 1.2% low-melting agarose in PBS with 100 µL of a 1 × 106 cells/
mL suspension in PBS kept at 37 °C. The coverslip was removed and 80 µL was
added on top of the first layer, spread with a coverslip, and left to solidify at 4 °C for
5–10 minutes. Two slides were made for each condition. The coverslips were again
removed and the cells were lysed in lysis buffer (8.8 mM Tris-NaOH, pH 10, 2.2 M
NaCl, 88.9 mM EDTA, 10% DMSO, and 1% Triton X-100) overnight at 4 °C in a
microscopy slide staining jar, protected from light. The following morning, the
slides were washed carefully with enzyme assay buffer (40 mM HEPES-KOH, pH
8.0, 0.1 M KCl, 0.5 mM EDTA and 0.2 mg/mL bovine serum albumin (BSA]) three
times. The agarose was then covered with 100 µL of 0.8 µg/mL recombinant
hOGG1 in enzyme assay buffer (or just assay buffer for controls), protected with a
coverslip and incubated for 45 min at 37 °C. The slides were denatured in
electrophoresis buffer (0.3N NaOH, 1 mM EDTA) for 30 min in a Comet Assay
Tank (Thistle Scientific) at room temperature in the dark, followed by
electrophoresis for 30 min at 25V and 300mA. Finally, the slides were incubated
for 45 min in neutralization buffer (0.4 M Tris-HCl, pH 7.5). Immediately before
microscopy, 60 µL of SYBR Gold dye (Life Technologies, 1:1000 in PBS) was added
to each sample.
The slides were visualized using a 10x objective and a Zeiss LSM 780 confocal or
Zeiss Axiovert 35 microscope. Comets were analyzed with OpenComet (www.
cometbio.org/) or Comet Assay IV (http://www.perceptive.co.uk/products/comet-
assay-iv/) software and the tail moments (tail length x percent DNA in the tail)
were automatically calculated. The tail moments were normalized to the buffer
control for the siNon-targeting+DMSO or DMSO group to obtain relative tail
moments. At least 100 cells were analyzed for each condition per replicate.
Western blotting. Cells were lysed directly in 1× Laemmli buffer, boiled and
sonicated. Proteins were separated by SDS-PAGE with 4–15% Mini-PROTEAN
TGX gels and transferred to nitrocellulose with a Trans-Blot Turbo machine (Bio-
Rad). Blocking of was performed with Li-Cor Blocking Buffer. Primary antibodies
were incubated overnight at 4 °C in 1:1 Li-Cor Blocking Buffer/TBS + 0.05% Tween
20 (TBS-T) at the following concentrations: anti-NUDT5 (EZBiolabs + lab-pur-
ified, 1:1000), β-actin (Abcam, 1:5000), SOD1 (Santa Cruz, 1:1000) and MTH1
(Novus Biologicals, 1:1000). Secondary antibodies were diluted at 1:15 000 in 1:1
Li-Cor blocking buffer/TBS-T and incubated for 1 h at room temperature. Bands
were visualized with an Odyssey Fc Imager and analyzed with Image Studio
Software (Li-Cor Biosciences). All uncropped western blots from this manuscript
are compiled in Supplementary Figure 12.
Immunofluorescence. Following siRNA knockdown for 48 h, 10 000 U-2 OS cells
were seeded per well in black, clear-bottomed 96-well plates (BD Falcon) and
allowed to grow for an additional 48 h. For inhibitor treatment experiments, cells
were plated at 2000 per well and 10 µM TH5427 was added the following day for an
additional 72 h. Cells were washed with PBS and then fixed with 4% paraf-
ormaldehyde in PBS (Santa Cruz) with 0.5% Triton X-100 for 15 min. Primary
antibodies were γH2A.X (Millipore, 1:1000 or Cell Signaling, 1:1000), 53BP1
(Bethyl, 1:1000 or Abcam, 1:500) and RPA32 (Cell Signaling, 1:1000) diluted in 3%
BSA/PBS and incubated at 4 °C overnight. Alexa Fluor secondary antibodies
(ThermoFisher) were used at 1:1000 diluted in 3% BSA/PBS for 1 h at room
temperature. DNA was counterstained with DAPI and plates were visualized using
an ImageXpress high-throughput microscope (Molecular Devices) with 20x
objective. Image analysis was performed with CellProfiler software (Broad
Institute).
Small molecule screening campaign. Details regarding the small molecule
screening campaign for NUDT5 inhibitors are described in the Supplementary
Methods.
Synthesis of inhibitors. NUDT5 inhibitors were synthesized according to the
methods described in the Supplementary Methods.
Target engagement analyses. Differential scanning fluorimetry (DSF)5,47 was
performed with 5 µM purified NUDT5, 20 µM NUDT5 inhibitor and 5x Sypro
Orange added per well added to a 96-well PCR plate. Each experiment was per-
formed in duplicate. Temperature gradients from 25 to 95 °C (increasing at a rate
of 1 °C per minute) were completed with readings every minute on a CFX96 Real-
Time PCR machine (Bio-Rad). Melting temperatures were determined as the
minimum of the negative first derivative plots with CFX Maestro software (Bio-
Rad).
Target engagement in cells was determined by the cellular thermal shift assay
(CETSA)29. Briefly, cell lysate thermal shift assays were performed with 1 × 106
HL-60 cells per temperature/condition. Cells were collected and washed once with
PBS and resuspended in TBS with protease inhibitor cocktail (Mini cOmplete,
EDTA-free, Roche) at 60 µL/1 × 106 cells. The cells were then aliquoted and lysed
by freeze-thawing three times with 3-min incubations (3x, 3 min.+3 min.) using an
ethanol/dry ice bath and water bath at 37 °C. The lysates were then centrifuged at
20,000×g for 20 min at 4 °C to remove cellular debris. Supernatants were then
transferred to PCR strip tubes and treated with 0.5 µL DMSO (0.8% v/v final) or 20
µM inhibitor for 20 min at room temperature. Lysates with compounds were
heated at the indicated temperature in a Veriti Thermal Cycler (Applied
Biosystems) for 3 min, then cooled for another 3 min at room temperature. They
were then centrifuged at 20 000 × g for 20 min at 4 °C to pellet protein aggregates
and 45 µL was removed and prepared for western blotting analysis.
For CETSA experiments with cells treated in culture, 1 × 106 HL-60 were
treated with DMSO (0.1 % v/v final) or 20 µM compound for 3 h at 37 °C and 5%
CO2 in a humidified incubator. T47DWT cells were treated instead with 80 µM
TH1659, 15 µM TH5423/5424 and 1.5 µM TH5427. The cells were harvested,
washed twice with PBS and resuspended in TBS with protease inhibitors, as above.
Heating was identical as before, except that immediately following heating, the cell
suspensions were snap frozen in a dry ice/ethanol bath and freeze-thawed, as
previously, to lyse cells. Centrifugation at 20 000 × g for 20 min at 4 °C removed
cellular debris and protein aggregates, and lysates were prepared for western
blotting.
Treatments, heating and lysis procedures for ITDRFCETSA were performed
identically to those for CETSA experiments, except NUDT5 inhibitors were added
to cells at serial dilutions from 20 to 0.06 µM. Curves were fit by sigmoidal dose-
response (variable slope) to derive EC50 values in GraphPad Prism 7.
To determine membrane integrity and cell viability at the temperatures used for
CETSA experiments, HL-60 cells were heated identically to CETSA experiments
and the cells were resuspended in 40 µg/mL propidium iodide (PI). The cells were
analyzed on a Navios flow cytometer with Kaluza software (Becton Dickenson).
Target engagement was also determined by drug affinity responsive target
stability (DARTS)33. HL-60 cells were treated in culture with DMSO (0.1% v/v) or
TH5427 at 0.7 or 2.2 µM for 4 h. Following two PBS washes, the cells were lysed
with M-PER extraction buffer (ThermoFisher) supplemented with protease
inhibitor cocktail (Roche). The lysates were divided into 20 µg aliquots and
followed by digestion with pronase at the indicated protein to pronase ratios for 30
min at room temperature. Samples were prepared for western blotting and
NUDT5 stabilization was compared with SOD1 as a loading control.
Cell viability assays. Cell viability was assessed by resazurin9. 5000 HL-60 cells (or
1000 U-2 OS/2000 T47D cells) were seeded per well on a 96-well plate. The
following morning, compounds (or the equivalent amount of DMSO) were added
to obtain the final concentrations indicated and the cells were incubated at 37 °C
for 72 h with resazurin added at 0.02 mg/mL for the last 2–6 h. Resorufin fluor-
escence was detected at 600 nM with a Hidex Sense fluorescent plate reader.
Viability curves were fit using the sigmoidal dose-response (variable slope) function
in GraphPad Prism 7.
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Crystal structures of NUDT5 bound to ligands. The structure of NUDT5 in
complex with inhibitors TH1713 and TH5427 was determined from single crystal
x-ray diffraction of truncated NUDT5 with residues 1–210 (26 mg/ml in 0.1 M
HEPES, pH 7.5, 300 mM NaCl, 10% glycerol, and 1 mM TCEP). Sitting drop vapor
diffusion experiments were performed at 18 °C, and NUDT5 was mixed with
reservoir solution (0.1 M Na Citrate pH 6.2, 0.15 M ammonium acetate, 33% PEG
3350) in a 1:1 ratio. Once crystals were formed dry inhibitor was added to the
crystal drop and incubated for 24–48 h. Diffraction quality crystals were extracted
and flash frozen in liquid nitrogen. Both data sets were collected at the 14.1
beamline at BESSY II (Berlin, Germany) at 100 K and 0.92 Å wavelength. Data
reduction and processing were carried out using XDS48 and programs from the
CCP4 suite49. Both structures were solved via molecular replacement with NUDT5
PDBID 3AC9. Initial models were built using Phenix AutoBuild program50 and
CCP4 Arp/wARP51, followed by iterative building cycles using the Refine program
in Phenix52. Both structures were solved in the C 1 2 1 space group with two
molecules in the asymmetric unit forming the NUDT5 functional dimer. Supple-
mentary Figure 5 contains an alternative view of the NUDT5 dimer bound with
TH1713 (a), electron density maps for TH1713 and TH5427 bound in the active
site (b) and stereo views of the TH1713 and TH5427 electron densities (c). Relevant
crystallography statistics are shown in Table 1. The coordinates and structure
factors for the structures presented in this paper were deposited in the PDB under
code 5NQR (NUDT5_TH1713) and 5NWH (NUDT5_TH5427).
Selectivity assays for TH5427. The selectivity assay for TH5427 against similar
pyrophosphohydrolases was performed with MTH1, NUDT9, NUDT2, NUDT12,
NUDT14, NUDT15, NUDT18, ITPase, dCTPase and dUTPase9. All analyses were
performed by malachite green assay following 30 min incubation at room tem-
perature in reaction buffer (100 mM Tris Acetate, pH 7.5, 40 mM NaCl, 10 mM
MgAc, 1 mM DTT) with 100 µM TH5427 and preferred substrates for each enzyme
(4.75 nM MTH1 with 100 µM dGTP, 8 nM NUDT15 with 100 µM dGTP, 8 nM
NUDT2 with 16 µM AP4A, 2 nM NUDT5 with 50 µM ADPR, 20 nM NUDT9 with
50 µM ADPR, 20 nM NUDT12 with 50 µM NADH, 2 nM NUDT14 with 50 µM
ADPR, 200 nM NUDT18 with 50 µM 8-oxo-dGTP, 0.2 nM ITPase with 25 µM, 35
nM dCTPase with 35 µM dCTP, and 1 nM dUTPase with 12.5 µM dUTP). MTH1,
NUDT15, NUDT18, ITPase, dCTPase and dUTPase reactions were coupled with
0.2 U/mL pyrophosphatase, while NUDT2, NUDT5, NUDT9, NUDT12, and
NUDT14 reactions were coupled by bovine intestinal phosphatase (10 U/mL).
TH5427 selectivity was also studied with the SafetyScreen44™ Panel and
ExpresSDiversity Kinase Panel from Eurofins Cerep Panlabs at 10 µM, according to
the company’s procedures.
Preparation of 32P-PAR. 32P-NAD-labeled PAR was prepared as follows: 5 µg of
purified GST-PARP1 was incubated with 2 µg of activated calf thymus DNA and
10mM NAD +/32P-NAD (Perkin-Elmer) at a ratio of 1:10 for 30 min at 25 °C and
brought to a final volume of 100 µL with PARP reaction buffer (50 mM Tris, pH
7.5, 50 mM NaCl, 0.5 mM DTT, 0.1% Triton X-100 and protease inhibitors)23.
After incubation, 0.4 µg of DNase was added to obtain DNA-free probes and the
reaction was precipitated using TCA. The pellet was washed with acetone, dried
and resuspended in 100 µl (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1 % SDS, 100
µg/mL of Proteinase K) and incubated for 1 h at 37 °C, after which radio-labeled
PAR was extracted using phenol/chloroform and ethanol precipitation. The pellet
was resuspended in 50 µL (10 mM Tris-HCl, pH 8.0, 1 mM EDTA) and used for
subsequent biochemical analyses.
Biochemical conversion of ADPR to ATP by NUDT5. Enzymatic conversion of
radiolabeled 32P-PAR by PARG and NUDT5 was performed using purified radio-
labeled PAR (as described above) with the addition of recombinant bovine PARG
in PAR glycohydroxylation buffer (PGB; 10 mM HEPES, pH 7.5, 150 mM KCl, 10
mM MgCl2)23. Recombinant PARG was added at the beginning of the reaction to a
10 µL final volume and incubated for 1 h at 25 °C. Recombinant NUDT5, pyr-
ophosphate and/or TH5427 (0.6 µM) were added as indicated and incubated for an
additional hour. Following termination of the reactions (95 °C for 2 min), products
were visualized by spotting a fraction onto polyethyleneimine (PEI)-cellulose plates
(Macherey-Nagel, Polygram CEL 300 PEI/UV254), and resolved in 0.3 M KH2PO4
at pH 3.5. Dried TLC plates were exposed on phosphoscreens and scanned using a
Typhoon Trio (Amersham Biosciences).
ATP visualization using bioluminescence imaging. T47DWT cells were seeded in
RPMI in black-walled 96-well plates and transfected using Lipofectamine 2000®
(Invitrogen, manufacturer’s instructions) with the nuclear-targeted luciferase
constructs (Nuc-luc FRTTO53) at a final concentration of 50 ng DNA/well for 48 h.
16 h prior to hormone (R5020, 10 nM) exposure, cells were synchronized by serum
starvation. Bioluminescence was activated by addition of 100 µl D-luciferin (1 mg/
mL water, Sigma) and ATP was quantified using an IVIS system (Xenogen Corp).
Histone H1 displacement by chromatin immunoprecipitation. ChIP assays were
performed using a histone H1-specific antibody, AE4 (Abcam)54. 1 × 107 T47DM
cells (plated and treated with hormone and/or inhibitor, as described above) were
cross-linked for 10 min with 1% formaldehyde. Lysates were sonicated (Biorupter
sonicator, Diagenode) resulting in DNA fragments with a size range of 200-300 bp.
Histone H1 was immunoprecipitated from 50 μg of chromatin and 40 μL of Protein
A-Agarose Beads (Diagenode) in IP Buffer (100 mM NaCl, 50 mM Tris-HCl, pH
8.0, 5 mM EDTA and 0.5% SDS) with protease inhibitors (11836170001, Roche),
and this was incubated for 16 h with end-over-end rotation at 4 °C. The beads were
washed 3-fold with low salt buffer (140 mM NaCl, 50 mM HEPES, pH 7.4, 1%
Triton X-100), twice with high salt buffer (500 mM NaCl, 50 mM HEPES, pH 7.4,
1% Triton X-100) and once with LiCl Buffer (10 mM Tris-HCl, pH 8.0, 250 mM
LiCl, 1% NP-40, 1% sodium deoxycholic acid and 1 mM EDTA) and 1X TE buffer
at 4 °C. Crosslinks were reversed at 65 °C overnight and the immunoprecipitated
DNA was purified using phenol-chloroform and ethanol precipitation. The
resultant eluted DNA was quantified by Qubit 3.0 Fluorometer (Life Technologies)
and qPCR (LightCycler FastStart DNA Master SYBR Green I, Roche). The fold
enrichment of target sequences in the immunoprecipitated (IP) compared to input
(I) fractions were calculated using the comparative Ct method (2Ct(IP)−Ct(I)).
Values are referred to as relative abundance over time zero (no R5020 treatment).
Primer sequences are available on request.
Progesterone-dependent gene expression by RT–qPCR. Total RNA and cDNA
were prepared using an RNeasy Plus kit (Qiagen) and Superscript II kit (Invitro-
gen), respectively, according to the manufacturers’ instructions54. Quantification of
mRNA abundance of specific gene products was performed by RT-qPCR (Light-
Cycler FastStart DNA Master SYBR Green I), normalized to GAPDH and
expressed as relative RNA abundance over time zero (no R5020 treatment). Primer
sequences are available upon request.
Proliferation analysis following R5020 treatment by BrdU. T47DM cells (1 ×
104) were plated in a 96-well plate in the presence or absence of inhibitors 2 h prior
to R5020 addition. The cell proliferation ELISA BrdU chemiluminescent assay
(Roche) was performed according to the manufacturer’s instructions 24 h following
hormone addition.
Statistical analyses. Statistical analyses for relevant experiments were performed
as follows with GraphPad Prism 7 software. The DNA damage markers in Fig. 1c
were analyzed by Kruskal–Wallis test with Dunn’s correction for multiple com-
parisons (n = 3; HγH2A.X, 45.28, HRPA, 71.3, H53BP1, 5.061). Those in Supplementary
Fig. 11a were analyzed by Mann-Whitney test, two-tailed (n = 2; UγH2A.X, 3086667,
URPA, 777581, U53BP1, 3714547). The alkaline comet assays were analyzed by
Kruskal-Wallis test with Dunn’s correction for multiple comparisons and OGG1-
treated samples were compared to DMSO or siNeg controls (n = 2 per set in
duplicate; HFig1d, 326.2, HSFig11b, 328.8, HSFig11c, 63.73). All analyses for CETSA
experiments was performed by one-way ANOVA with Dunnett’s correction for
multiple comparisons of n = 2 repeats (dfFig3c, 9, dfSFig4d, 7, dfSFig10a, 9; FFig3c, 12.99,
FSFig4d, 80.73, FSFig10a, 5.331). ITDRFCETSA experiments for TH5427 were per-
formed n = 3 times. CETSA melt curves and ITDRFCETSA curves were fit by sig-
moidal dose-response (variable slope) to derive EC50 values. Nuclear
bioluminescence experiments were analyzed by repeated measures two-way
ANOVA with Dunnett’s correction for multiple comparisons and represent n = 6
repeats (Total df, 287; Finteraction, 2.385, Ftime, 18.38, Ftreatment, 3.474, Fsubjects
(matching), 12.56). mRNA expression was log-transformed and analyzed by one-way
ANOVA with Dunnett’s correction for multiple comparisons (n = 3 for
progesterone-dependent genes, n = 2 for progesterone-independent genes; dfEGFR,
11, dfMMTV-luc, 11, dfCCNB1, 7, dfRBM24, 7; FEGFR, 10.73, FMMTV-luc, 6.587, FCCNB1,
1.139, FRBM24, 0.2468). Cell proliferation experiments with BrdU labeling (n = 2)
were analyzed by one-way ANOVA with Dunnett’s correction for multiple com-
parisons (dfStarved, 7, df+ R5020, 7; FStarved, 0.7637, F+ R5020, 247.93). In all cases, NS
not significant, *p < 0.05, **p< 0.01, ***p< 0.001 and ****p< 0.0001. With
experiments analyzed post hoc for multiple comparisons, adjusted p-values are
reported. Error bars represent SEM in all cases, except for substrate screening,
ChIP and viability experiments, which indicate the SD and are intended to
represent the variation among replicates/independent experiments.
Data availability. Materials, protocols and other supporting data used in this study
may be obtained from the corresponding authors upon reasonable request. The
coordinates and structure factors for the structures presented in this paper were
deposited in the PDB under code 5NQR (NUDT5_TH1713) and 5NWH
(NUDT5_TH5427).
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